AZD5069   Click here for help

GtoPdb Ligand ID: 8948

Synonyms: AZD-5069
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AZD5069 is a novel, selective antagonist of the chemokine receptor, CXCR2. The structure shown here was drawn from that in [6], which specifies stereochemistry. This structure is identical to Example 47 in patent US7838675 [1]. PubChem records the structure with no specified stereochemistry (CID 59558839).
Small-molecule antagonists of CXCR2 are being developed for their potential to treat inflammatory conditions.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 158.56
Molecular weight 476.1
XLogP 1.73
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OCC(C(Oc1nc(SCc2cccc(c2F)F)nc(c1)NS(=O)(=O)N1CCC1)C)O
Isomeric SMILES OC[C@@H]([C@H](Oc1nc(SCc2cccc(c2F)F)nc(c1)NS(=O)(=O)N1CCC1)C)O
InChI InChI=1S/C18H22F2N4O5S2/c1-11(14(26)9-25)29-16-8-15(23-31(27,28)24-6-3-7-24)21-18(22-16)30-10-12-4-2-5-13(19)17(12)20/h2,4-5,8,11,14,25-26H,3,6-7,9-10H2,1H3,(H,21,22,23)/t11-,14+/m1/s1
InChI Key QZECRCLSIGFCIO-RISCZKNCSA-N
No information available.
Summary of Clinical Use Click here for help
AZD5069 is being evaluated in Phase 2 clinical trials for inflammatory conditions and oncology indications. This compound has been extensively studied as an anti-inflammatory agent in chronic respiratory diseases, including severe asthma [7,10], COPD [4,8] and bronchiectasis [2]. Trials combining AZD5069 with the anti-PD-L1 immune checkpoint inhibitor durvalumab are underway in patients with metastatic pancreatic ductal adenocarcinoma (NCT02583477, Phase 1/2) and metastatic squamous cell carcinoma of the head and neck and other solid tumours (NCT02499328, Phase 1/2). For a list of all current AZD5069 trials, visit ClinicalTrials.gov.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02499328 Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck Phase 1/Phase 2 Interventional AstraZeneca
NCT02583477 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Phase 1/Phase 2 Interventional AstraZeneca